IP Library › Granted Patent US 12,324,829
Granted Patent B2
US 12,324,829 · App. 15/903,861 · Granted Jun 10, 2025

Methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders

Inventors: Douglas M. McCarty (Pataskala, OH); Haiyan Fu (Pataskala, OH)
Assignee: NATIONWIDE CHILDREN'S HOSPITAL, INC.
A61K38/46A61K35/761A61K47/26A61K48/005C12N7/00C12N9/14C12N15/86C12N2750/14121C12N2750/14143C12N2750/14171C12Y310/01001
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,324,829
App. No.
15/903,861
Granted
Jun 10, 2025
Kind
B2
Abstract

The present invention relates to methods and materials useful for systemically delivering polynucleotides across the blood brain barrier using adeno-associated virus as a vector. For example, the present invention relates to methods and materials useful for systemically delivering α-N-acetylglucosamidinase polynucleotides to the central and peripheral nervous systems, as well as the somatic system. Use of these methods and materials is indicated, for example, for treatment of the lysosomal storage disorder mucopolysaccharidosis IIIB. As another example, the present invention relates to methods and materials useful for systemically delivering N-sulphoglucosamine sulfphohydrolase polynucleotides to the central and peripheral nervous systems, as well as the somatic system. Use of this second type of methods and materials is indicated, for example, for treatment of the lysosomal storage disorder mucopolysaccharidosis IIIA.

Claims (13)

1. A method of treating a patient having mucopolysaccharidosis IIIA (MPS IIIA), the method comprising:

intravenously administering a dose of about 1×10 13 to about 1×10 16 vg/kg of a self-complementary recombinant adeno-associated virus 9 (rAAV9) vector comprising a polynucleotide sequence that has at least 99% sequence identity to the polynucleotide sequence consisting of SEQ ID NO: 3 encoding a biologically active N-sulphoglucosamine sulphohydrolase (N-SGSH) polypeptide,

wherein the polynucleotide sequence is operably linked to a promoter,

wherein the vector is delivered across the blood-brain barrier (BBB) to the central nervous system (CNS) without mannitol pretreatment,

wherein the administration results in sustained expression of the encoded biologically active N-SGSH polypeptide in neurons and glia of the patient, and

wherein the sustained expression of the N-SGSH polypeptide in neurons and glia of the patient is effective to treat the patient having MPS IIIA.

2. The method of claim 1 , wherein the dose is about 1.0×10 13 vg/kg.

3. The method of claim 1 , wherein the rAAV9 vector comprises the polynucleotide sequence consisting of SEQ ID NO: 3.

4. The method of claim 1 , wherein the dose is about 3.0×10 13 vg/kg.

5. The method of claim 1 , wherein the dose is about 1.0×10 14 vg/kg.

6. The method of claim 1 , wherein the dose is about 1.0×10 15 vg/kg.

7. The method of claim 1 , wherein the dose is about 1.0×10 16 vg/kg.

8. The method of claim 1 , wherein the promoter is a CMV promoter or a U1a promoter.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2018
From: MCCARTY, DOUGLAS M.; FU, HAIYAN
To: NATIONWIDE CHILDREN'S HOSPITAL, INC.
Reel/Frame 046465/0544 →
Continuity (5)
Continuation 14950387 · Nov 24, 2015
Continuation 13922915 · Jun 20, 2013
Division 13491326 · Jun 7, 2012
Provisional Application 61494635 · Jun 8, 2011
Related Publication 20180193431A1 · Jul 12, 2018
References Cited (280)
US 5173414A · Lebkowski et al. · 1992 [cited by applicant]
US 5658776A · Flotte et al. · 1997 [cited by applicant]
US 5786211A · Johnson · 1998 [cited by applicant]
US 5863782A · Hopwood · 1999 [cited by examiner]
US 5871982A · Wilson et al. · 1999 [cited by applicant]
US 6258595B1 · Gao et al. · 2001 [cited by applicant]
US 6566118B1 · Atkinson et al. · 2003 [cited by applicant]
US 6582692B1 · Podsakoff et al. · 2003 [cited by applicant]
US 6841357B1 · Vaillancourt et al. · 2005 [cited by applicant]
US 7198951B2 · Gao et al. · 2007 [cited by applicant]
US 7906111B2 · Wilson et al. · 2011 [cited by applicant]
US 8999948B2 · Tubert · 2015 [cited by examiner]
US 9415121B2 · Kaspar et al. · 2016 [cited by applicant]
US 9725716B2 · Burghes et al. · 2017 [cited by applicant]
US 9926574B2 · Barkats · 2018 [cited by applicant]
US 10208318B2 · Barkats · 2019 [cited by applicant]
US 10301648B2 · Vandenberghe et al. · 2019 [cited by applicant]
US 10738326B2 · Muramatsu · 2020 [cited by applicant]
US 20030083299A1 · Ferguson · 2003 [cited by applicant]
US 20030118556A1 · Kaspar et al. · 2003 [cited by applicant]
US 20040076613A1 · Mazarakis et al. · 2004 [cited by applicant]
US 20050014262A1 · Gao et al. · 2005 [cited by applicant]
US 20050053922A1 · Schaffer et al. · 2005 [cited by applicant]
US 20070036760A1 · Wilson et al. · 2007 [cited by applicant]
US 20070280906A1 · Petras · 2007 [cited by applicant]
US 20080176799A1 · Ferguson et al. · 2008 [cited by applicant]
US 20090162332A1 · Davidson et al. · 2009 [cited by applicant]
US 20090202490A1 · Schaffer et al. · 2009 [cited by applicant]
US 20100130594A1 · Barkats · 2010 [cited by applicant]
US 20100240739A1 · Barkats · 2010 [cited by examiner]
US 20120177605A1 · Kaspar · 2012 [cited by examiner]
US 20130039888A1 · McCarty et al. · 2013 [cited by applicant]
US 20130158104A1 · Tubert et al. · 2013 [cited by applicant]
US 20130195800A1 · Roeth et al. · 2013 [cited by applicant]
US 20130195801A1 · Gao et al. · 2013 [cited by applicant]
US 20130224836A1 · Muramatsu · 2013 [cited by applicant]
US 20130225666A1 · Kaspar et al. · 2013 [cited by applicant]
US 20130296532A1 · Hermens et al. · 2013 [cited by applicant]
US 20130302308A1 · Ballabio · 2013 [cited by examiner]
US 20150252384A1 · Kaspar et al. · 2015 [cited by applicant]
US 20160038613A1 · Kaspar et al. · 2016 [cited by applicant]
US 20170216458A1 · Kaspar et al. · 2017 [cited by applicant]
US 20180036431A1 · Kaspar et al. · 2018 [cited by applicant]
EP 1620133A1 · 2006 [cited by applicant]
JP 2007527427A · 2007 [cited by applicant]
JP 2007528424A · 2007 [cited by applicant]
WO WO1995013365A1 · 1995 [cited by applicant]
WO WO1995013392A1 · 1995 [cited by applicant]
WO WO1996017947A1 · 1996 [cited by applicant]
WO WO1997006243A1 · 1997 [cited by applicant]
WO WO1997008298A1 · 1997 [cited by applicant]
WO WO199708308A1 · 1997 [cited by applicant]
WO WO1997009441A2 · 1997 [cited by applicant]
WO WO1997021825A1 · 1997 [cited by applicant]
WO WO1998009657A3 · 1998 [cited by applicant]
WO WO1999011764A3 · 1999 [cited by applicant]
WO WO2001083692A3 · 2002 [cited by applicant]
WO WO2002081634A2 · 2002 [cited by applicant]
WO WO2005033321A2 · 2005 [cited by applicant]
WO WO2005056807A2 · 2005 [cited by applicant]
WO WO2005084713A2 · 2005 [cited by applicant]
WO WO2005087272A2 · 2005 [cited by applicant]
WO WO2007089632A2 · 2007 [cited by applicant]
WO WO2008154198A1 · 2008 [cited by applicant]
WO WO2009013290A1 · 2009 [cited by applicant]
WO WO2009043936A1 · 2009 [cited by applicant]
WO WO2009137006A3 · 2010 [cited by applicant]
WO WO2010071832A1 · 2010 [cited by applicant]
WO WO2010129021A1 · 2010 [cited by applicant]
WO WO2011112902A2 · 2011 [cited by applicant]
WO WO2011133890A1 · 2011 [cited by applicant]
WO WO2012057363A1 · 2012 [cited by applicant]
WO WO2019108856A1 · 2019 [cited by applicant]
WO WO2019108857A1 · 2019 [cited by applicant]
Ruzo et al.XVIII Annual Congress of the European Society of Gene and Cell Therapy: 1389 (Abstract Or 96) p. 1 (Year: 2010). [cited by examiner]
NCBI accession No. U30894.1, p. 1 (Year: 1996). [cited by examiner]
Fraldi et al Human Molecular Genetics, vol. 16, No. 22 2693-2702 (Year: 2007). [cited by examiner]
Fu et al Molecular Therapy, 19(6), 1025-1033, 2011, published online, Mar. 8, 2011 (Year: 2011). [cited by examiner]
Fu et al Molecular Genetics and Metabolism, vol. 102, No. 2, pp. S18-S19. Abstract No. 118. Meeting Info: 7th Annual Research Meeting of the Lysosomal Disease Network, (Year: 2011). [cited by examiner]
Fu et al (Hereafter 3, Molecular Therapy, (May 2011) vol. 19, Supp. Suppl. 1, pp. S 131. Abstract No. 337. Meeting Info: 14th Annual Meeting of the American Society of Gene and Cell Therapy. Seattle, WA, United States. … [cited by examiner]
Duque et al Molecular Therapy vol. 17 No. 7, 1187-1196 (Year: 2009). [cited by examiner]
NCBI accession No. AY414351, pp. 1-2 (Year: 2003). [cited by examiner]
Sequence alignment of NCBI accession No. AY414351 vs SEQ ID No. 3, pp. 1-3 (Year: 2003). [cited by examiner]
Grimm et al Human Gene therapy, 2445-2450 (Year: 1999). [cited by examiner]
Heon-Roberts et al J. Clin. Med. 9, 344, 1-2 (Year: 2020). [cited by examiner]
NCBI accession No. AAA86530.1, pp. 1-2 (Year: 1996). [cited by examiner]
Fu et al (Molecular Therapy, 854, vol. 11, Supplement 1, S332 (Year: 2005). [cited by examiner]
Bhaumik et al., A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome), [cited by applicant]
Carter, Adeno-associated virus vectors, [cited by applicant]
Clark et al., A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors, [cited by applicant]
Clark et al., Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses, [cited by applicant]
Cressant et al., Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum, [cited by applicant]
De et al., High levels of persistent expression of a1-antitrypsin mediated by the nonhuman primate serotype rh. 10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses, [cited by applicant]
De Jong et al., Dimethylmethylene blue-based specrophotometry of glycosaminoglycans in untreated urng: a rapid screening procedure for mucopolysaccharidoses, [cited by applicant]
Duque et al., Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons, [cited by applicant]
Foust et al., Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes, [cited by applicant]
Fraldi et al., Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes, [cited by applicant]
Fu et al., Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery, [cited by applicant]
Fu et al., Neurological correction of lysosomal storage in a mucopolysaccharidosis IIB mouse model by adeno-associated virus-mediated gene delivery, [cited by applicant]
Fu et al., Restoration of central nervous system α-N-acetylglucosaminidase activity and therapeutic benefits in mucopolysaccharidosis IIB mice by a single intracisternal recombinant adeno-associated virus type 2 vector … [cited by applicant]
Fu et al., Significantly increased lifespan and improved behavioral performances by rAAV gene delivery in adult mucopolysaccharidosis IIIB mice, [cited by applicant]
Fu et al., Molecular Genetics and Metabolism, (Feb. 2011) vol. 102, No. 2, pp. S18-S19. Abstract No. 118. Meeting Info: 7th Annual Research Meeting of the Lysosomal Disease Netword, WORLD Symposium 2011, Las Vegas, NV (… [cited by applicant]
Fu et al., Molecular Therapy, (May 2011) vol. 19, Supp. Suppl. 1, p. S131. Abstract No. 337. Meeting Info: 14th Annual Meeting of the American Society of Gene and Cell Therapy. Seattle, WA. USA. May 18, 2011-May 21, 201… [cited by applicant]
Fu et al., Self-complementary adeno-associated virus serotype 2 vector: Global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain. [cited by applicant]
Gao et al., Clades of adeno-associated viruses are widely disseminated in human tissues, [cited by applicant]
GenBank Accession No. AF085716. [cited by applicant]
GenBank Accession No. AX753249. [cited by applicant]
GenBank Accession No. NC_00 1862. [cited by applicant]
GenBank Accession No. NC_001401. [cited by applicant]
GenBank Accession No. NC_001829. [cited by applicant]
GenBank Accession No. NC_002077. [cited by applicant]
GenBank Accession Nos. AX753246. [cited by applicant]
Guide for the Care and Use of Laboratory Animals [DHHS Publication No. (NIH) 85-23]. [cited by applicant]
Hartung et al., Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human α-L-Iduronidase gene, [cited by applicant]
Heldermon et al., Therapeutic efficacy of bone marrow transplant, intracranial AAV-mediated gene therapy, or both in the mouse model of MPS IIIB, [cited by applicant]
Hermonat et al., Use of adeno-associated virus as a mammalian DNA cloning vector: Transduction of neomycin resistance into mammalian tissue culture cells, [cited by applicant]
Kaplitt et al., Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: An open label, phase I trial, [cited by applicant]
Laughlin et al., Cloning of infectious adeno-associated virus genomes in bacterial plasmids, [cited by applicant]
Lebkowski et al., Adeno-associated virus: a vector system for efficient introduction and integration of DNA into a variety of mammalian cell types, [cited by applicant]
Lehninger, Chapter 4. The amino acid building blocks of proteins, Biochemistry, 2nd Edition; Worth Publishers, Inc., New York, pp. 71-77 (1975). [cited by applicant]
Li et al., Mouse model of sanfilippo syndrome type B produced by targeted disruption of the gene encoding α-N-acetylglucosaminidase, [cited by applicant]
Lijam et al., Social interaction and sensorimotor gating abnormalities in mice lacking Dvl1, [cited by applicant]
Manfredsson et al., AAV9: A potential blood-brain barrier buster. [cited by applicant]
Marks et al., Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: An open-label, phase I trial, [cited by applicant]
McCarty et al., Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice, [cited by applicant]
McLaughlin et al., Adeno-associated virus general transduction vectors: analysis of proviral structures, [cited by applicant]
Mori et al., Two novel adeno-associated viruses from cynomolgus monkey: Pseudotyping characterization of capsid protein, [cited by applicant]
Muzyczka, Use of adeno-associated virus as a general transduction vector for mammalian cells, [cited by applicant]
NCBI Accession No. U30894.1, dated Feb. 2, 1996 (2 pages). [cited by applicant]
Pacak et al., Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo, [cited by applicant]
Palli et al., Improved ecdysone receptor-based inducible gene regulation system, [cited by applicant]
Paul et al., Increased viral titer through concentration of viral harvests from retroviral packaging lines, [cited by applicant]
Perrin et al., An experimental rabies vaccine produced with a new BHK-21 suspension cell culture process: Use of serum-free medium and perfusion-reactor system [cited by applicant]
Ruffing et al., Mutations in the carboxy terminus of adeno-associated virus 2 capsid proteins affect viral infectivity: Lack of an RGD integrin-binding motif, [cited by applicant]
Ruzo et al., Liver production of sulfamidase reverses peripheral and ameliorates CNS pathology in mucopolysaccharidosis IIIA mice, [cited by applicant]
Ruzo et al., XVIII Annual Congress of the European Society of Gene and Cell Therapy: 1389 (Abstract Or 96) (Oct. 22-25, 2010). [cited by applicant]
Sambrook et al., Molecular Cloning: A Laboratory Manual (Second ed., Cold Spring Harbor Laboratory Press, 1989), Hybridization of radiolabeled probes to immobilized nucleic acids, §§ 9.47-9.51. [cited by applicant]
Samulski et al., Cloning of adeno-associated virus into pBR322: Rescue of intact virus from the recombinant plasmid in human cells, [cited by applicant]
Samulski et al., Helper-free stocks of recombinant adeno-associated viruses: Normal integration does not require viral gene expression, [cited by applicant]
Sands et al., CNS-directed gene therapy for lysosomal storage diseases, [cited by applicant]
Sands et al., Percutaneous intravenous injection in neonatal mice, [cited by applicant]
Schenpp and Clark, Highly purified recombinant adeno-associated virus vectors, [cited by applicant]
Senapathy & Carter, Molecular cloning of adeno-associated virus variant genomes and generation of infectious virus by recombination in mammalian cells, [cited by applicant]
Srivastava et al., Nucleotide sequence and organization of the adeno-associated virus 2 genome, [cited by applicant]
Tratschin et al., A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenical acetyltransferase, [cited by applicant]
Tratschin et al., Adeno-associated virus vector for high-frequency integration, expression, and rescue of genes in mammalian cells, [cited by applicant]
Urlinger et al., Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity, [cited by applicant]
Van de Lest et al., Quantification and characterization of glycosaminoglycans at the nanogram level by a combined azure A-silver staining in agarose gels, [cited by applicant]
Wang et al., Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart, [cited by applicant]
Warburton et al., The conjoint importance of the hippocampus and anterior thalamic nuclei for allocentric spatial learning: Evidence from a disconnection study in the rat, [cited by applicant]
Worgall et al., Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA, [cited by applicant]
Zincarelli et al., Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection, [cited by applicant]
Zolotukhin et al., Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield, [cited by applicant]
Bevan et al., Early heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery, [cited by applicant]
Foust et al., Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN, [cited by applicant]
Mingozzi et al., Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges, [cited by applicant]
Suzuki et al., Are animal models useful for understanding the pathophysiology of lysosomal storage disease? [cited by applicant]
Verma et al., Routes of drug administration, [cited by applicant]
Walkley, Cellular pathology of lysosomal storage disorders, [cited by applicant]
Xiao et al., Gene therapy vectors based on adeno-associated virus type 1, [cited by applicant]
Dehouck et al., An easier, reproducible, and mass-production method to study the blood-brain barrier in vitro, [cited by applicant]
Del Gaudio et al., Increased MECP2 gene copy number as the result of genomic duplication in neurodevelopmentally delayed males, [cited by applicant]
Dodge et al., Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity, [cited by applicant]
Eck et al., Gene-based therapy, Chapter 5 pp. 77-101, In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, New York, NY: McGraw Hill (1996). [cited by applicant]
Examination Report, Australian patent application No. 2013296425, May 22, 2017. [cited by applicant]
Federici et al., Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs, [cited by applicant]
Ford, Selected maturational changes observed in the postnatal rat brain, [cited by applicant]
Friez et al., Recurrent infections, hypotonia, and mental retardation caused by duplication of MECP2 and adjacent region in Xq28, [cited by applicant]
Gadalla et al., Improved survival and reduced phenotypic severity following AAV9/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice, [cited by applicant]
Gavrilina et al., Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle-specific SMN expression has no phenotypic effect, [cited by applicant]
Grady et al., Cerebellar synaptic defects and abnormal motor behavior in mice lacking alpha- and beta-dystrobrevin, [cited by applicant]
Gray et al., Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-comprised blood-brain barrier (BBB), [cited by applicant]
Gray et al., Gene Therapy and neurodevelopmental disorders, [cited by applicant]
Gray et al., Viral vectors and delivery strategies for CNS gene therapy, [cited by applicant]
Grossman et al., A randomized comparison of iodixanol and iohexol in adult intracranial computed tomography scanning, [cited by applicant]
Guy et al., A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome, [cited by applicant]
Guy et al., Reversal of neurological defects in a mouse model of Rett syndrome, [cited by applicant]
Haseloff et al., In search of the astrocytic factor(s) modulating blood-brain barrier functions in brain capillary endothelial cells in vitro, [cited by applicant]
Hawkins et al., The blood-brain barrier/neurovascular unit in health and disease, [cited by applicant]
Hayashi et al., Induction of various blood-brain barrier properties in non-neural endothelial cells by close apposition to co-cultured astrocytes, [cited by applicant]
Hsieh-Li et al., A mouse model for spinal muscular atrophy, [cited by applicant]
Hutson et al., Corticospinal tract transduction: a comparison of seven adenoassociated viral vector serotypes and a non-integrating lentiviral vector, [cited by applicant]
Iadecola, Neurovascular regulation in the normal brain and in Alzheimer's disease, [cited by applicant]
Inagaki et al., Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8, [cited by applicant]
International Application No. PCT/US13/53065, International Preliminary Report on Patentability, dated Feb. 3, 2015. [cited by applicant]
International Application No. PCT/US09/68818, International Search Report and Written Opinion, mailing date Mar. 2, 2010. [cited by applicant]
International Application No. PCT/US13/53065, International Search Report and Written Opinion, mailed Sep. 2, 2013. [cited by applicant]
International Application No. PCT/US2009/068818, International Preliminary Report on Patentability, dated Jun. 21, 2011. [cited by applicant]
Japanese Patent Application No. 2015-525565, Notice of Reasons for Rejection, dated May 16, 2017. [cited by applicant]
Japanese Patent Application No. 2018-058524, Notice of Reasons for Rejection, dated Dec. 27, 2018. [cited by applicant]
Kaiser, Clinical research. Death prompts a review of gene therapy vector, [cited by applicant]
Kaminsky and Ascano, p. 1-4 (2017). [cited by applicant]
Kaspar et al., Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model, [cited by applicant]
Katz et al., Preclinical research in Rett syndrome: setting the foundation for translational success, [cited by applicant]
Kempermann et al., Genetic influence on neurogenesis in the dentate gyrus of adult mice, [cited by applicant]
Kim et al., Trendelenburg position with hip flexion as a rescue strategy to increase spinal anaesthetic level after spinal block, [cited by applicant]
Klein et al., AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method, [cited by applicant]
Koerber et al., Molecular Evolution of Adeno-associated Virus for Enhanced Glial Gene Delivery, [cited by applicant]
Kohan et al., Therapeutic approaches to the challenge of neuronal ceroid lipofuscinoses, [cited by applicant]
Kong et al., Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice, [cited by applicant]
Kosai et al., Rett syndome is reversible and treatable by MeCP2 gene therapy into the striatum in mice, [cited by applicant]
Kota et al., Follistatin gene delivery enhances muscle growth and strength in nonhuman primates, [cited by applicant]
Le et al., SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN, [cited by applicant]
Lioy et al., A role for glia in the progression of Rett's syndrome, [cited by applicant]
Maguire et al., Directed evolution of adeno-associated virus for glioma cell transduction, [cited by applicant]
McAllister et al., Mechanisms of glucose transport at the blood-brain barrier: an in vitro study, [cited by applicant]
McIlwain, “Chemical and enzymic make-up of the brain during development” In: Mcllwain, Biochemistry and the Central Nervous System, London: Churchill Livingstone (1966). [cited by applicant]
Monani et al., A transgene carrying an A2G missense mutation in the SMN gene modulates phenotypic severity in mice with severe (type I) spinal muscular atrophy, [cited by applicant]
Monani et al., The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy, [cited by applicant]
Nagai et al., A transcriptional repressor MeCP2 causing Rett syndrome is expressed in embryonic non-neuronal cells and controls their growth, Brain Res., [cited by applicant]
Narver et al., Sustained improvement of spinal muscular atrophy mice treated with trichostatin A plus nutrition, [cited by applicant]
Notice of Reasons for Rejection (English translation), Japanese patent application No. 2015/525565, mailed May 16, 2017. [cited by applicant]
Oertle et al., Nogo-A inhibits neurite outgrowth and cell spreading with three discrete regions, [cited by applicant]
Oprea et al., Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy, [cited by applicant]
Pardridge, Drug and gene targeting to the brain with molecular Trojan horses, [cited by applicant]
Penta, Sulla colorazione vitale del sistema nervoso central negli animali neonati, [cited by applicant]
Perabo et al., Combinatorial engineering of a gene therapy vector: directed evolution of adeno-associated virus, [cited by applicant]
Ralph et al., Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model, [cited by applicant]
Rastegar et al., MECP2 isoform-specific vectors with regulated expression for Rett syndrome gene therapy, [cited by applicant]
Reichenbach et al., pp. 19-35 In: Kettemann et al., Neuroglia, 2nd ed., New York: Oxford University Press (2004). [cited by applicant]
Risau et al., Development of the blood-brain barrier, [cited by applicant]
Risau et al., Differentiation-dependent expression of proteins in brain endothelium during development of the blood-brain barrier, [cited by applicant]
Robinson et al., Morphological and functional reversal of phenotypes in a mouse model of Rett syndrome, [cited by applicant]
Royo et al., Specific AAV serotypes stably transduce primary hippocampal and cortical cultures with high efficiency and low toxicity, [cited by applicant]
Rubin et al., A cell culture model of the blood-brain barrier, [cited by applicant]
Saunders et al., On the progestational activity of 17alpha-ethynyl-17-hydroxy-5(10)-estren-3-one (norethynodrel), [cited by applicant]
Schlageter et al., Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties, [cited by applicant]
Setayesh et al., The Trendelenburg position increases the spread and accelerates the onset of epidural anesthesia for Cesarean section, [cited by applicant]
Siegel et al., Francis Crick's legacy for neuroscience: between the alpha and the Omega, [cited by applicant]
Sinnett et al., Recent endeavors in MECP2 gene transfer for gene therapy of Rett syndrome, [cited by applicant]
Skene et al., Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state, [cited by applicant]
Snyder et al., Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery, [cited by applicant]
Sobue et al., Induction of blood-brain barrier properties in immortalized bovine brain endothelial cells by astrocytic factors, [cited by applicant]
Stern et al., Platelet lipoxygenase in spontaneously hypertensive rats, [cited by applicant]
Stewart et al., Interendothelial junctional changes underlie the developmental ‘tightening’ of the blood-brain barrier, [cited by applicant]
Turner et al., Administration of substances to laboratory animals: routes of administration and factors to consider, [cited by applicant]
Verkman, Aquaporin water channels and endothelial cell function, [cited by applicant]
Virgintino et al., Immunolocalization of tight junction proteins in the adult and developing human brain, Histochem. [cited by applicant]
Vorbrodt et al., Localization of alkaline phosphatase activity in endothelia of developing and mature mouse blood-brain barrier, [cited by applicant]
Wang et al., Decreased synaptic activity shifts the calcium dependence of release at the mammalian neuromuscular junction in vivo, [cited by applicant]
Watson et al., Postnatal growth and morphological development of the brain: a species comparison, [cited by applicant]
Wolburg et al., Tight junctions of the blood-brain barrier: development, composition and regulation, [cited by applicant]
Wolburg, pp. 77-107 In: Dermietzel et al., (eds.), Blood-Brain Interfaces—from Ontogeny to Artificial Barriers, Wiley-VCH (2006). [cited by applicant]
Wu et al., Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes, [cited by applicant]
Yamanaka et al., Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis, [cited by applicant]
Carter, “Adeno-Associated Virus Vectors in Clinical Trials”, Human Gene Therapy, 16:541-550 (2005). [cited by applicant]
Carty et al., Convection-Enhanced Delivery and Systemic Mannitol Increase Gene Products Distribution of AAV Vectors 5, 8, and 9 and Increase Gene Product in the Adult Mouse Brain, [cited by applicant]
Dalkara et al. “In Vivo-Directed Evolution of a New Adeno-Associated Virus for Therapeutic Outer Retinal Gene Deliver from the Vitreous,” Science Translational Medicine, 5(189):1-11 (2013). [cited by applicant]
Edelstein et al., “Gene therapy clinical trials worldwide 1989-2004-an overview”, The Journal of Gene Medicine, 6:597-602 (2004). [cited by applicant]
Final Rejection issued in U.S. Appl. No. 16/159,986 dated Mar. 4, 2021. [cited by applicant]
Maguire et al., “Gene Therapy for the Nervous System: Challenges and New Strategies,” Neurotherapeutics, 11:817-839 (2004). [cited by applicant]
Ruzo et al., “AAV-Mediated Sulphamidase Expression in Liver or Skeletal Muscle Prevents Development of Somatic Alterations in MPS IIIA Mice,” Molecular Therapy, 16(1):S197 (2008). [cited by applicant]
Storek et al., “Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain”, PNAS, 105(3):1055-1060 (2008). [cited by applicant]
Towne et al., “Recombinant adeno-associated virus serotype 6 (rAAV2/6)-mediated gene transfer to nociceptive neurons through different routes of delivery”, Molecular Pain, 5(52):1-17 (2009). [cited by applicant]
Yogalingam et al., “Molecular Genetics of Mucopolysaccharidosis Type IIIA and IIIB: Diagnostic, Clinical, and Biological Implications,” [cited by applicant]
Akbar et al., The role of MR myelography with intrathecal gadolinium in localization of spinal CSF leaks in patients with spontaneous intracranial hypotension, [cited by applicant]
Amicus Therapeutics, Amicus establishes gene therapy pipeline for lysosomal storage disorders (LSDs). Sep. 20, 2018, p. 1-27 (2018). [cited by applicant]
Bowerman et al., Therapeutic strategies for spinal muscular atrophy: SMN and beyond, [cited by applicant]
Dayton et al., The advent of AAV9 expands applications for brain and spinal cord gene delivery, [cited by applicant]
De los Reyes et al., Abstract #204. Interim Results from the First Clinical Gene Therapy Trial for CLN6 Batten Disease. Forty- Eighth National Meeting of the Child Neurology Society. Charlotte, NC. Oct. 23-26, 2019. [cited by applicant]
Drory et al., EEG Recordings Following Intrathecal lohexol Administration, [cited by applicant]
Gao et al., Mutations in a novel CLN6-encoded transmembrane protein cause variant neuronal ceroid lipofuscinosis in man and mouse, [cited by applicant]
Gray et al., Preclinical Differences of Intravascular AAV9 Delivery to Neurons and Glia: A Comparative Study of Adult Mice and Nonhuman Primates, [cited by applicant]
Haria et al., lohexol a review of its pharmacological properties and use as a contrast medium in Myelography and Neuroangiography, [cited by applicant]
Highlights of Prescribing Information Omnipaque-iohexol injection, GE Healthcare Inc. (May 2018). [cited by applicant]
Hudry et al., Therapeutic AAV gene transfer to the nervous system: A clinical reality, [cited by applicant]
McCarty et al., Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo, [cited by applicant]
McCarty et al., Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis, [cited by applicant]
Olsen et al., Intrathecal iohexol-distribution following cervical myelography, postmyelographic registration of adverse effects, psychometric assessment and electroencephalographic recording, [cited by applicant]
Papisov et al., Physiology of the intrathecal bolus: the leptomeningeal route for macromolecule and particle delivery to CNS, [cited by applicant]
Ratcliff et al., Cognitive and affective changes after myelography: A Comparison of Metrizamide and lohexol, [cited by applicant]
Schuster et al., Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after intrathecal and intravenous delivery in mouse, [cited by applicant]
Steinfeld et al., Late Infantile Neuronal Ceroid Lipofuscinosis: Quantitative Description of the Clinical Course in Patients With CLN2 Mutations, [cited by applicant]
Su et al., Real-time MR imaging with Gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors, [cited by applicant]
Vestergaard et al., Central Nervous System Reactions to Cervical Myelography, [cited by applicant]
Wang et al., Expansive gene transfer in the rat CNS rapidly produces amyotrophic lateral sclerosis relevant sequelae when TDP-43 is overexpressed, [cited by applicant]
Zhang et al., Several rAAV Vectors Efficiently Cross the Blood-brain Barrier and Transduce Neurons and Astrocytes in the Neonatal Mouse Central Nervous System, [cited by applicant]
NCBI accession No. U43573.1, Human alpha-N-acetylglucosaminidase (NAGLU) mRNA, complete cds, pp. 1-2 (Year: 1996). [cited by applicant]
Sequence alignment of SEQ ID No. 1 vs accession No. U43573.1, pp. 1-3 (Year: 2021). [cited by applicant]
Fu et al., Significantly increased lifespan and improved behavioral performances by rAAV gene delivery in adult mucopolysaccharidosis IIIB mice Gene Therapy 14:1065-77 (2007). [cited by applicant]